BIOLOGY OF NON-HUMAN PRIMATE MARROW STROMAL CELLS
BIOLOGY OF NON-HUMAN PRIMATE MARROW STROMAL CELLS
批准号:
7716203
负责人:
Bruce A. Bunnell
金额:
$2.4万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-21 至 2009-04-30
关键词:
AdipocytesAdipose tissueAffectAgingAlzheimer&aposs DiseaseAneuploidyAnimal ModelApoptosisBiologyBone MarrowCatabolismCell CycleCell Cycle CheckpointCell Differentiation processCellsCharacteristicsChildChondrocytesClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseDNA Polymerase IIDataDevelopmentDiseaseEngineeringEngraftmentFrequenciesFundingGene ExpressionGene Expression ProfileGenesGenetic TranscriptionGoalsGrantHeart failureHome environmentHumanImmuneImmunodeficient MouseIn VitroInfusion proceduresInstitutionKaryotypeLaboratoriesMacaca mulattaMarrowMesenchymal Stem CellsMusNeuronsOntologyOsteoblastsOsteoporosisParkinsonian DisordersPathway interactionsPatientsPatternPhasePolyploidyPopulationPrimatesProceduresPropertyProteinsProtocols documentationRare DiseasesRegulationResearchResearch PersonnelResourcesSourceStem cellsStromal CellsTestingTissuesUbiquitinationUnited States National Institutes of HealthVirusadult stem cellagedcell injurycell typedaygene therapyhuman diseaseimprovedin vivointerestleukodystrophynonhuman primateranpirnaserelating to nervous system
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
该项目的总体目标是开发程序,使来自骨髓基质的成年干细胞可以用于非人类灵长类动物的基因治疗试验。成体干细胞,称为间充质干细胞或骨髓基质细胞(MSCs),对细胞和基因治疗感兴趣,因为它们可以很容易地从患者那里获得,在培养中扩增,使用或不使用病毒进行基因工程,然后返回治疗同一患者。它们也是令人感兴趣的,因为它们是受损组织的家园,并分化以取代组织中受损的细胞。这些细胞目前正在许多人类疾病的小动物模型中进行测试,几项有希望的临床试验已经启动,用于治疗儿童罕见疾病。然而,在非人类灵长类动物中进行广泛的细胞试验,显然对于目前提出的一些用于常见疾病的应用是必不可少的,例如骨质疏松症、心力衰竭、帕金森氏症、脑白质营养不良和阿尔茨海默病。该提案的目标是:
具体目的1.用我们实验室最近开发的分离和扩增人MSCs的改良方法分离和扩增灵长类MSCs。我们已经成功地从恒河猴的骨髓和脂肪组织中分离出骨髓间充质干细胞。我们对干细胞群体的体外生物学特性进行了广泛的表征。我们的数据表明,来自这两个组织的MSCs具有许多共同的特征。人骨髓间充质干细胞(HASCs)和恒河猴骨髓间充质干细胞(RBMSCs)比人骨髓间充质干细胞(HBMSCs)和恒河猴骨髓间充质干细胞(RASCs)经历更多的群体倍增。随着体外培养时间的延长,所有MSCs的细胞周期曲线都发生了变化。人骨髓间充质干细胞在P20和P30的S期细胞频率增加。然而,这两种来源的恒河猴MSCs在P20时形成了明显的多倍体细胞群,到P30时发展为非整倍体。骨髓间充质干细胞的核型分析显示,在P20或P30时,恒河猴细胞出现了四倍体或非整倍体核型。对早期和晚期传代的MSCs的转录组分析显示,基因表达模式发生了显著变化(8.8%的基因在hBMSCs和hASCs中差异表达;5.5%的基因在rBMSCs和rASCs中差异表达)。随着年龄的增长,同一细胞类型的基因表达变化不那么明显(在hMSCs中为0.7%,在rMSCs中为0.9%)。基因本体论分析表明,参与蛋白质分解代谢和PolII转录调控的功能在rASCs中过度表达,而I?B/NF-B级联调控在hBMSCs中过度表达。对rASCs和hBMSCs中差异表达基因的功能分析表明,参与细胞周期、细胞周期检查点、蛋白质泛素化和细胞凋亡的通路发生了改变。总体而言,来自这两个物种和组织来源的MSCs的体外特征显示出高水平的共同生物学特性。然而,结果也显示出明显的生物学差异。
具体目的2.比较培养中的灵长类MSCs和人类MSCs的快速扩增和分化为成骨细胞、软骨细胞、脂肪细胞和神经细胞的能力。我们发现恒河猴细胞可以有效地沿着成骨、成软骨和成脂的方向分化。人类和恒河猴骨髓间充质干细胞的效率几乎没有区别。在神经分化方面,我们发现恒河猴ASCs在体外沿着这一谱系分化的效率高于人类或骨髓来源的细胞。
具体目的3.比较灵长类MSCs和体内人MSCs在全身或颅内注射给免疫缺陷小鼠后植入多组织的能力。这些研究目前正在进行中。我们已经使用立体定位的方法将人和恒河猴的骨髓和脂肪组织来源的MSCs注射到NIHIII和Twitcher(Krabbe感染)小鼠的中枢神经系统中。我们目前正在评估这些细胞在中枢神经系统的植入和分化。来自免疫缺陷小鼠的数据表明,细胞植入后可持续180天,并沿神经谱系经历适度分化。目前正在收集有关Twitcher老鼠研究的数据。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The overall aim of the project is to develop procedures whereby adult stem cells from the bone marrow stroma can be used for trials of gene therapy in non-human primates. The adult stem cells, referred to as mesenchymal stem cells or marrow stromal cells (MSCs), are of interest for cell and gene therapy because they can readily be obtained from a patient, expanded in culture, genetically engineered with or without the use of viruses, and then returned for therapy of the same patient. They are also of interest because they home to damaged tissues and differentiate to replace the damaged cells in the tissues. The cells are currently being tested in many small animal models of human diseases and several promising clinical trials with the cells have been initiated in rare diseases in children. However, extensive trials of the cells in non-human primates are clearly essential for some of the currently proposed applications to common diseases such as osteoporosis, cardiac failure, Parkinsonism, leukodystrophies, and Alzheimer's disease. The goals of the proposal are:
Specific Aim 1. Isolate and expand primate MSCs with the improved protocol our laboratory has recently developed to isolate and expand cultures of human MSCs. We have successfully isolated rhesus MSCs from both the bone marrow and adipose tissue. We have done an extensive characterization of the in vitro biologic properties of the stem cell populations. Our data indicate that the MSCs from these two tissues share many characteristics. Human ASCs (hASCs) and rhesus BMSCs (rBMSCs) undergo significantly more total population doublings than human BMSCs (hBMSCs) and rhesus ASCs (rASCs). The cell cycle profile of all MSCs is altered as cultures aged in vitro. hMSCs underwent an increase in the frequency of cells in the S phase at P20 and P30. However, rhesus MSCs from both sources developed a distinct polyploid population of cells at P20, which progressed to aneuploidy by P30. Karyotype analysis of MSCs revealed the development of tetraploid or aneuploid karyotypes in the rhesus cells at P20 or P30. Analysis of the transcriptome of the MSCs from early and late passages revealed significant alterations in the patterns of gene expression (8.8% of the genes were differentially expressed in hBMSCs vs. hASCs; and 5.5% in rBMSCs vs. rASCs). Gene expression changes were much less evident within the same cell type as aging occurred (0.7% in hMSCs and 0.9% in rMSCs). Gene ontology analysis showed that functions involved in protein catabolism and regulation of pol II transcription were over-represented in rASCs, while the regulation of I¿B/NF-¿B cascade were over-represented in hBMSCs. Functional analysis of genes that were differentially expressed in rASCs and hBMSCs revealed that pathways involved in cell-cycle, cell cycle checkpoints, protein-ubiquitination, and apoptosis were altered. Overall in vitro characterization of MSCs from these two species and tissue sources revealed a high level of common biologic properties. However, the results demonstrate clear biologic distinctions, as well.
Specific Aim 2. Compare the primate MSCs in culture with human MSCs in their ability to expand rapidly and to differentiate into osteoblasts, chondrocytes, adipocytes, and neural cells. We have found that the rhesus cells efficiently undergo differentiation along osteogenic, chondrogenic and adipogenic lineages. The efficiency between the human and rhesus MSCs is virtually indistinguishable. In terms of neural differentiation, we have found that rhesus ASCs differentiate along this lineage with greater efficiency in vitro than human or bone marrow derived cells.
Specific Aim 3. Compare the primate MSCs to human MSCs in vivo in their ability to engraft into multiple tissues after systemic or intracranial infusion into immunodeficient mice. These studies are currently ongoing. We have injected human and rhesus bone marrow and adipose tissue derived MSCs into the CNS of NIHIII AND Twitcher (Krabbe-affected) mice, using stereotaxic delivery. We are currently assessing engraftment and differentiation of these cells in the CNS. Data from the immune deficient mice indicate the cells engraft, persist for as long as 180 days and undergo moderate differentiation along neural lineages. Data on the Twitcher mouse studies is currently being collected.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Distinguishing adipose stromal vs. stem cells by serial transplantation
-
批准号:8511619
-
项目类别:
-
资助金额:$23.92万
-
财政年份:2012
-
负责人:Bruce A. Bunnell
-
依托单位:
SUBMUCOSAL SIV PERSISTENCE DESPITE HAART
-
批准号:8358138
-
项目类别:
-
资助金额:$4.51万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
CNS WHITE MATTER TRACTS AS A NOVEL AVENUE FOR GENE THERAPY FOR KRABBE DISEASE
-
批准号:8358155
-
项目类别:
-
资助金额:$2.9万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
IMMUNOPATHOLOGIC ALTERATIONS IN RHESUS MACAQUES WITH GLOBOID CELL LEUKODYSTROPHY
-
批准号:8358070
-
项目类别:
-
资助金额:$3.72万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
NONHUMAN PRIMATE MODEL FOR KRABBE'S DISEASE
-
批准号:8358078
-
项目类别:
-
资助金额:$3.72万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
BIOLOGY OF NON-HUMAN PRIMATE MARROW STROMAL CELLS
-
批准号:8358037
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
STEM CELL PRODUCTION CORE
-
批准号:8358074
-
项目类别:
-
资助金额:$3.72万
-
财政年份:2011
-
负责人:Bruce A. Bunnell
-
依托单位:
STEM CELL PRODUCTION CORE: ADULT ANIMAL MARROW STEM CELLS
-
批准号:8172969
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Bruce A. Bunnell
-
依托单位:
RHESUS SV40 ANTIOXIDANT GENE DELIVERY TO THE CNS
-
批准号:8173000
-
项目类别:
-
资助金额:$3.94万
-
财政年份:2010
-
负责人:Bruce A. Bunnell
-
依托单位:
IMMUNOPATHOLOGIC ALTERATIONS IN RHESUS MACAQUES WITH GLOBOID CELL LEUKODYSTROPHY
-
批准号:8172965
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Bruce A. Bunnell
-
依托单位:
BIOLOGY OF NON-HUMAN PRIMATE MARROW STROMAL CELLS
-
批准号:8172928
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Bruce A. Bunnell
-
依托单位:
NONHUMAN PRIMATE MODEL FOR KRABBE'S DISEASE
-
批准号:8172974
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Bruce A. Bunnell
-
依托单位:
NONHUMAN PRIMATE MODEL FOR KRABBE'S DISEASE
-
批准号:7958641
-
项目类别:
-
资助金额:$6.01万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
BIOLOGY OF NON-HUMAN PRIMATE MARROW STROMAL CELLS
-
批准号:7958585
-
项目类别:
-
资助金额:$6.01万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
STEM CELL PRODUCTION CORE: ADULT ANIMAL MARROW STEM CELLS
-
批准号:7958634
-
项目类别:
-
资助金额:$6.27万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
MESENCHYMAL STEM CELL THERAPY FOR DIABETES
-
批准号:7958622
-
项目类别:
-
资助金额:$3.48万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
RHESUS SV40 ANTIOXIDANT GENE DELIVERY TO THE CNS
-
批准号:7958682
-
项目类别:
-
资助金额:$3.63万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
IMMUNOPATHOLOGIC ALTERATIONS IN RHESUS MACAQUES WITH GLOBOID CELL LEUKODYSTROPHY
-
批准号:7958630
-
项目类别:
-
资助金额:$6.01万
-
财政年份:2009
-
负责人:Bruce A. Bunnell
-
依托单位:
VECTOR DEVELOPMENT AND PRODUCTION CORE FACILITY
-
批准号:7716263
-
项目类别:
-
资助金额:$2.4万
-
财政年份:2008
-
负责人:Bruce A. Bunnell
-
依托单位:
STEM CELL PRODUCTION CORE
-
批准号:7716264
-
项目类别:
-
资助金额:$2.4万
-
财政年份:2008
-
负责人:Bruce A. Bunnell
-
依托单位:
海外基金